Chapter 37: Role of Compounding Pharmacist

This chapter describes the role of the compounding pharmacist in NaProTECHNOLOGY, noting that many of its protocols use compounded medications prepared to a physician's specifications for an individual patient. The chapter reviews the history, definition, reasons for and regulation of compounding, including the litigation that ended with Section 503A of the 1997 Food and Drug Administration Modernization Act struck down in its entirety. The authors list questions for judging a compounding pharmacy's training and quality control and discuss bioidentical hormones, which the chapter describes as having the exact molecular structure of hormones made in the human body. The chapter states that Women's Health Initiative results cannot be extrapolated to all forms of hormone replacement therapy, especially bioidentical hormone replacement therapy, and that most compounded prescriptions are not cost prohibitive.